Parkinson’s News Today is providing virtual coverage of the 2023 Annual Meeting for the American Academy of Neurology taking place April 22-27 in Boston. Stay tuned to this page for all the latest news.
Abbvie is funding a clinical trial called PROSPECT to assess how clinical outcomes and disease burden change over time for people with Parkinson’s disease whose symptoms are not adequately controlled with available…
Read moreAn assay using skin biopsies, called the Syn-One Test, was able to detect the alpha-synuclein protein that characterizes Parkinson’s disease and like conditions in more than 90% of the patients enrolled in a…
People with Parkinson’s disease given deep brain stimulation (DBS) targeting the right side of the brain experienced fewer cognitive side effects following treatment compared with those who…
People prescribed certain medications to treat asthma or high blood pressure are less likely to develop Parkinson’s disease, according to an analysis of healthcare data in Norway. The finding implies these therapies may…
IPX203, Amneal Pharmaceuticals‘ investigational extended-release carbidopa/levodopa (CD/LD) treatment for Parkinson’s disease, continued to exhibit a favorable safety and efficacy profile during the open-label extension part of the Phase 3 RISE-PD trial. “IPX203…
Parkinson’s disease patients treated with prasinezumab for three years — as part of a long-term extension of the Phase 2 PASADENA clinical trial — were shown to be at a lower risk of…
DopaFuse, a continuous oral levodopa-carbidopa delivery system, led to more stable levels of medication in the blood and better control of symptoms for people with Parkinson’s disease in a small Phase 2…
Most people with Parkinson’s disease treated with SPN-830, an apomorphine infusion pump, report improvement in their health status. SPN-830 also reduced “off” time, when symptoms are not being adequately controlled, by…
Get regular updates to your inbox.